Application: Used as Sitagliptin Intermediates. We can provide CDMO services with sufficient capacity. Contact us at sales@huatengusa.com now.
Sitagliptin was the first oral DPP-4 inhibitor approved by the FDA for the treatment of T2D in October 2006.
I want to comment